Literature DB >> 26825471

Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.

Sotirios Tsimikas1.   

Abstract

PURPOSE OF REVIEW: This article summarizes recent observations on the role of lipoprotein(a) [Lp(a)] as a risk factor mediating cardiovascular disease. RECENT
FINDINGS: Lp(a) is a highly prevalent cardiovascular risk factor, with levels above 30 mg/dl affecting 20-30% of the global population. Up until now, no specific therapies have been developed to lower Lp(a) levels. Three major levels of evidence support the notion that elevated Lp(a) levels are a causal, independent, genetic risk factor for cardiovascular disease: epidemiologic studies and meta-analyses, genome-wide association studies and Mendelian randomization studies. Recent studies also have noted that individuals with low levels of Lp(a) are associated with a higher risk of incident type 2 diabetes mellitus, and conversely individuals with high levels have a lower risk, but this association does not appear to be causal. Novel therapies to lower Lp(a) include PCSK9 inhibitors and antisense oligonucleotides directly preventing translation of apolipoprotein(a) mRNA.
SUMMARY: With this robust and expanding clinical database, a reawakening of interest in Lp(a) as clinical risk factor is taking place. Trials are underway with novel drugs that substantially lower Lp(a) and may reduce its contribution to cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825471      PMCID: PMC5061509          DOI: 10.1097/MED.0000000000000237

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  47 in total

Review 1.  Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.

Authors:  Marlys L Koschinsky; Santica M Marcovina
Journal:  Curr Opin Lipidol       Date:  2004-04       Impact factor: 4.776

2.  Genetic variants in the apolipoprotein(a) gene and coronary heart disease.

Authors:  Yonghong Li; May M Luke; Dov Shiffman; James J Devlin
Journal:  Circ Cardiovasc Genet       Date:  2011-10

Review 3.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 4.  Lipoprotein(a): resurrected by genetics.

Authors:  F Kronenberg; G Utermann
Journal:  J Intern Med       Date:  2012-11-12       Impact factor: 8.989

5.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

6.  Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes.

Authors:  T Hiraga; T Kobayashi; M Okubo; K Nakanishi; T Sugimoto; Y Ohashi; T Murase
Journal:  Diabetes Care       Date:  1995-02       Impact factor: 19.112

7.  Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Authors:  Michelle L O'Donoghue; David A Morrow; Sotirios Tsimikas; Sarah Sloan; Angela F Ren; Elaine B Hoffman; Nihar R Desai; Scott D Solomon; Michael Domanski; Kiyohito Arai; Stephanie E Chiuve; Christopher P Cannon; Frank M Sacks; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

Review 8.  Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Authors:  Mark J Graham; Nick Viney; Rosanne M Crooke; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-11-04       Impact factor: 5.922

9.  The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Authors:  Manjinder S Sandhu; Nita G Forouhi; Zheng Ye; Philip C Haycock; Deepti Gurdasani; Cristina Pomilla; S Matthijs Boekholdt; Sotirios Tsimikas; Kay-Tee Khaw; Nicholas J Wareham
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

10.  Common variants associated with plasma triglycerides and risk for coronary artery disease.

Authors:  Ron Do; Cristen J Willer; Ellen M Schmidt; Sebanti Sengupta; Chi Gao; Gina M Peloso; Stefan Gustafsson; Stavroula Kanoni; Andrea Ganna; Jin Chen; Martin L Buchkovich; Samia Mora; Jacques S Beckmann; Jennifer L Bragg-Gresham; Hsing-Yi Chang; Ayşe Demirkan; Heleen M Den Hertog; Louise A Donnelly; Georg B Ehret; Tõnu Esko; Mary F Feitosa; Teresa Ferreira; Krista Fischer; Pierre Fontanillas; Ross M Fraser; Daniel F Freitag; Deepti Gurdasani; Kauko Heikkilä; Elina Hyppönen; Aaron Isaacs; Anne U Jackson; Asa Johansson; Toby Johnson; Marika Kaakinen; Johannes Kettunen; Marcus E Kleber; Xiaohui Li; Jian'an Luan; Leo-Pekka Lyytikäinen; Patrik K E Magnusson; Massimo Mangino; Evelin Mihailov; May E Montasser; Martina Müller-Nurasyid; Ilja M Nolte; Jeffrey R O'Connell; Cameron D Palmer; Markus Perola; Ann-Kristin Petersen; Serena Sanna; Richa Saxena; Susan K Service; Sonia Shah; Dmitry Shungin; Carlo Sidore; Ci Song; Rona J Strawbridge; Ida Surakka; Toshiko Tanaka; Tanya M Teslovich; Gudmar Thorleifsson; Evita G Van den Herik; Benjamin F Voight; Kelly A Volcik; Lindsay L Waite; Andrew Wong; Ying Wu; Weihua Zhang; Devin Absher; Gershim Asiki; Inês Barroso; Latonya F Been; Jennifer L Bolton; Lori L Bonnycastle; Paolo Brambilla; Mary S Burnett; Giancarlo Cesana; Maria Dimitriou; Alex S F Doney; Angela Döring; Paul Elliott; Stephen E Epstein; Gudmundur Ingi Eyjolfsson; Bruna Gigante; Mark O Goodarzi; Harald Grallert; Martha L Gravito; Christopher J Groves; Göran Hallmans; Anna-Liisa Hartikainen; Caroline Hayward; Dena Hernandez; Andrew A Hicks; Hilma Holm; Yi-Jen Hung; Thomas Illig; Michelle R Jones; Pontiano Kaleebu; John J P Kastelein; Kay-Tee Khaw; Eric Kim; Norman Klopp; Pirjo Komulainen; Meena Kumari; Claudia Langenberg; Terho Lehtimäki; Shih-Yi Lin; Jaana Lindström; Ruth J F Loos; François Mach; Wendy L McArdle; Christa Meisinger; Braxton D Mitchell; Gabrielle Müller; Ramaiah Nagaraja; Narisu Narisu; Tuomo V M Nieminen; Rebecca N Nsubuga; Isleifur Olafsson; Ken K Ong; Aarno Palotie; Theodore Papamarkou; Cristina Pomilla; Anneli Pouta; Daniel J Rader; Muredach P Reilly; Paul M Ridker; Fernando Rivadeneira; Igor Rudan; Aimo Ruokonen; Nilesh Samani; Hubert Scharnagl; Janet Seeley; Kaisa Silander; Alena Stančáková; Kathleen Stirrups; Amy J Swift; Laurence Tiret; Andre G Uitterlinden; L Joost van Pelt; Sailaja Vedantam; Nicholas Wainwright; Cisca Wijmenga; Sarah H Wild; Gonneke Willemsen; Tom Wilsgaard; James F Wilson; Elizabeth H Young; Jing Hua Zhao; Linda S Adair; Dominique Arveiler; Themistocles L Assimes; Stefania Bandinelli; Franklyn Bennett; Murielle Bochud; Bernhard O Boehm; Dorret I Boomsma; Ingrid B Borecki; Stefan R Bornstein; Pascal Bovet; Michel Burnier; Harry Campbell; Aravinda Chakravarti; John C Chambers; Yii-Der Ida Chen; Francis S Collins; Richard S Cooper; John Danesh; George Dedoussis; Ulf de Faire; Alan B Feranil; Jean Ferrières; Luigi Ferrucci; Nelson B Freimer; Christian Gieger; Leif C Groop; Vilmundur Gudnason; Ulf Gyllensten; Anders Hamsten; Tamara B Harris; Aroon Hingorani; Joel N Hirschhorn; Albert Hofman; G Kees Hovingh; Chao Agnes Hsiung; Steve E Humphries; Steven C Hunt; Kristian Hveem; Carlos Iribarren; Marjo-Riitta Järvelin; Antti Jula; Mika Kähönen; Jaakko Kaprio; Antero Kesäniemi; Mika Kivimaki; Jaspal S Kooner; Peter J Koudstaal; Ronald M Krauss; Diana Kuh; Johanna Kuusisto; Kirsten O Kyvik; Markku Laakso; Timo A Lakka; Lars Lind; Cecilia M Lindgren; Nicholas G Martin; Winfried März; Mark I McCarthy; Colin A McKenzie; Pierre Meneton; Andres Metspalu; Leena Moilanen; Andrew D Morris; Patricia B Munroe; Inger Njølstad; Nancy L Pedersen; Chris Power; Peter P Pramstaller; Jackie F Price; Bruce M Psaty; Thomas Quertermous; Rainer Rauramaa; Danish Saleheen; Veikko Salomaa; Dharambir K Sanghera; Jouko Saramies; Peter E H Schwarz; Wayne H-H Sheu; Alan R Shuldiner; Agneta Siegbahn; Tim D Spector; Kari Stefansson; David P Strachan; Bamidele O Tayo; Elena Tremoli; Jaakko Tuomilehto; Matti Uusitupa; Cornelia M van Duijn; Peter Vollenweider; Lars Wallentin; Nicholas J Wareham; John B Whitfield; Bruce H R Wolffenbuttel; David Altshuler; Jose M Ordovas; Eric Boerwinkle; Colin N A Palmer; Unnur Thorsteinsdottir; Daniel I Chasman; Jerome I Rotter; Paul W Franks; Samuli Ripatti; L Adrienne Cupples; Manjinder S Sandhu; Stephen S Rich; Michael Boehnke; Panos Deloukas; Karen L Mohlke; Erik Ingelsson; Goncalo R Abecasis; Mark J Daly; Benjamin M Neale; Sekar Kathiresan
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more
  14 in total

Review 1.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 2.  Towards more specific treatment for diabetic dyslipidemia.

Authors:  Valentina Rodriguez; Jonathan D Newman; Arthur Z Schwartzbard
Journal:  Curr Opin Lipidol       Date:  2018-08       Impact factor: 4.776

Review 3.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

4.  Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study.

Authors:  Mohammad Reza Mahmoodi; Hamid Najafipour
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

Review 5.  Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 4.810

Review 6.  The art of cardiovascular risk assessment.

Authors:  Jay Khambhati; Marc Allard-Ratick; Devinder Dhindsa; Suegene Lee; John Chen; Pratik B Sandesara; Wesley O'Neal; Arshed A Quyyumi; Nathan D Wong; Roger S Blumenthal; Laurence S Sperling
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

Review 7.  Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.

Authors:  Dhrubajyoti Bandyopadhyay; Kumar Ashish; Adrija Hajra; Arshna Qureshi; Raktim K Ghosh
Journal:  J Lipids       Date:  2018-03-25

8.  Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases.

Authors:  Jianhong Lu; Buxing Chen; Tingting Chen; Shuyuan Guo; Xinli Xue; Qun Chen; Mingming Zhao; Lin Xia; Zhengjiang Zhu; Lemin Zheng; Huiyong Yin
Journal:  Redox Biol       Date:  2017-04-26       Impact factor: 11.799

9.  Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.

Authors:  Rutger Verbeek; Renate M Hoogeveen; Anne Langsted; Lotte C A Stiekema; Simone L Verweij; G Kees Hovingh; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Børge G Nordestgaard; Erik S G Stroes
Journal:  Eur Heart J       Date:  2018-07-14       Impact factor: 29.983

10.  High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients.

Authors:  I Dewa Gde Dwi Sumarjaya; I Ketut Badjra Nadha; Anak Agung Wiradewi Lestari
Journal:  Vasc Health Risk Manag       Date:  2020-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.